



Northern Lincolnshire  
Area Prescribing Committee

## The Northern Lincolnshire Area Prescribing Committee

# MINUTES

28 April 2022  
2.00 pm via Teams

## **1 Introductions**

Osman Ali (OA) – Lead Pharmacist High Cost Drugs & Procurement (NLaG)  
Oliver Fillingham (OF) – Pharmacist (NECS)  
Paulash Haider (PH) – Assistant Chief Pharmacist (NLaG)  
Andy Karvot (AK) – Northern Lincolnshire Interface Pharmacist (NLaG)  
Jane Morgan (JM) – Principal Pharmacist – Formulary, Interface & Medicines Commissioning (HUTH)  
Dr Pothina (NP) – Consultant Diabetologist (NLaG) – Chair  
Simon Priestley (SP) – Chief Pharmacist (NLaG)  
Dr A Sinha (AS) – Clinical Lead for Adult Services in NEL  
Rachel Staniforth (RMS) – Medicines Optimisation Pharmacist (NECS)  
Sally Uren (SU) – Pharmacist (NECS)

### **In Attendance:**

Joanne Rowson - Minute Taker (NLaG)

## **2 Apologies**

Apologies were received from:

Andrea Fraser (AF) - General Practitioner LMC  
Caroline Hayward (CH) – Professional Development Pharmacist Humber LPC  
Sarah Spooner (SS) – Clinical Lead Care Plus Group  
Hazel Tait (HT) – Contracts Manager (NLaG)

## **3 Declarations of Pecuniary Interest**

There were no declarations of pecuniary interest.

## **4 Minutes of Previous Meeting held on 10 March 2022**

The minutes of the previous meeting held on 10 March 2022 were accepted as a true record with the exception of 'Mr' Chakraborty not 'Dr'.

## **5 Action Log & Matters Arising not on the action log**

- a) Overactive Bladder in Female Patients – sent out with draft minutes for approval/comments. No comments received and to be ratified at this meeting. Noted that for the purpose of completeness the last box on the flow chart on page 2 should be updated to 'refer to Secondary Care' and be more prominent. Header to be amended as there was a query as to whether it was a 'pathway' or 'guideline' (it was felt that 'guideline' was appropriate). Reference to combination therapy should include a reference to the evidence base for this to the college guidance that this came from. AK to refer this back to the Urologists. This should then go back to M&T and then the new Humber APC for approval. **Action: AK**
- b) Modafanil – Item withdrawn from discussions.

Action log updated accordingly.

## 6 APC Working Arrangements

- a) NICE TA & CG Updates – Live document updated accordingly and was for the information of the committee.

Cenobamate – HERPC classify this as blue which translates as Amber 2 on the new joint formulary. Noted that Doncaster and Sheffield have classed it as a shared care guideline which would be at variance with what HUTH have classified it as. JM would look at this further and the item would be deferred to the next joint formulary meeting with recommendation of classification of Amber 2. Noted that NICE required implementation was March 2022 with Primary Care taking on prescribing by June at the earliest.

- b) Newsletter – no newsletter for April.
- c) Sharing of APC Agenda/Minutes and decisions – information shared.
- d) NHS Net Zero – no update. Wider discussions held in Humber APC.

## 7 Requests, Amendments and Actions

- a) Blueteg – standing item on APC agenda. SU work continuing to roll out forms with Dermatology. Noted that these forms should be submitted to JM and AK for the new format.
- b) Chapter 4 Antipsychotics – This went to Humber APC.
- c) Gonadorelin Analogues – This was submitted by AK following April M&T. It was tabled that the Urologists would be interested in switching their gonadorelin analogue of choice to Triptorelin, because there is a 6 month preparation available which might produce discounts and save face to face appointments in Primary Care. This was approved at M&T and was now here for approval. The Committee were asked to approve for new patients from the Urologists, who initiate with the monthly preparation, then refer to GPs to prescribe the longer-acting. All three drugs in the document are on the formulary and this was thought to be more of a commissioning issue. More information would be required from the Urologists and then Primary Care costs can be looked at. PH would liaise with RMS after speaking to the Urologists regarding numbers. **Action: PH/RMS**
- d) Trimipramine de-prescribing guidance V1.1 – Some work had been done approximately 3 years ago regarding this and 7e below but since then this had dropped off the agenda. They had been updated and it was hoped to support these going forward. Any patients still on these medications are being flagged by the Medicines Optimisation Team to encourage conversations with the patients to highlight switches/support this. The items are not on the formulary and have not been dispensed in Secondary Care over the last few years. This was supported/approved.
- e) Dosulepin prescribing guidance V1.1 – as above with the addition of a link to the Northern Lincolnshire netFormulary antidepressants section, as in the trimipramine document.

8 **Items for General Notice:**

- a) MHRA Safety Updates & Spreadsheet – March 2022 for information.
- b) Regional Medicines Optimisation Committee (RMOC) quarterly cascade – no information.

9 **Items by Prior Notice:**

- a) Stoma Care Guidelines - Stoma Specialist Nurses and AK have updated the stoma care guidelines. AK will circulate this virtually to the group explaining what the three changes to the document have been and seek virtual approval before taking over to Humber APC and noting at M&T. Noted that the pricing was out of date and would be required to be updated to ensure that we are using the most cost-effective products.

**Date and Time of Next Meeting:**

**No more meetings will be held. Dr Pothina was thanked for all his work in the Chair role.**